HDAC9 and Ventricular arrhythmia: However, the four U. S. Food and Drug Administration (FDA) approved pan-HDAC inhibitors are limited to non-solid tumors and have been reported to cause serious cardiotoxicities such as QT interval prolongation, ventricular arrhythmia and unexpected sudden cardiac death [4,5,6,7].